Literature DB >> 6553695

An inherited defect in the C3 convertase, C3b,Bb, associated with glomerulonephritis.

H K Marder, T H Coleman, J Forristal, L Beischel, C D West.   

Abstract

The control of the amplification C3 convertase, C3b,Bb, of the serum complement system has been found to be defective in five members of a family spanning three generations. One of the five has membranoproliferative glomerulonephritis (MPGN) type III and another has mild idiopathic rapidly progressive glomerulonephritis. The defect is manifested by low serum concentrations of C3 and usually factor B with normal levels of the proteins which control the convertase, H and I. C3 nephritic factor (C3NeF) was not demonstrable. Enhanced C3 conversion was produced by the incubation of their serum at 37 degrees C for 30 min. This conversion was further accelerated by incubation after increasing the serum magnesium concentration by increments ranging from 0.25 to 1.9 mM. Incremental additions of H to serum depleted of H indicated that the amplification convertase of affected family members required more H for its inhibition than did that of normal subjects. This requirement was reduced by the addition of purified normal C3 but not by the addition of purified C3 of the propositus. It is postulated that affected family members are heterozygous for a gene producing an abnormal C3 which, as a constituent of the amplification convertase, C3b,Bb, confers resistance to H. Investigation of this apparently nephritogenic defect may provide insight into the pathogenesis of these glomerulonephritides.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6553695     DOI: 10.1038/ki.1983.89

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  15 in total

1.  Treatment with human complement factor H rapidly reverses renal complement deposition in factor H-deficient mice.

Authors:  Fadi Fakhouri; Elena Goicoechea de Jorge; Frédérique Brune; Philippe Azam; H Terence Cook; Matthew C Pickering
Journal:  Kidney Int       Date:  2010-05-05       Impact factor: 10.612

2.  Lack of complement activation by human IgA immune complexes.

Authors:  H Imai; A Chen; R J Wyatt; A Rifai
Journal:  Clin Exp Immunol       Date:  1988-09       Impact factor: 4.330

3.  MPGN II--genetically determined by defective complement regulation?

Authors:  Christoph Licht; Ursula Schlötzer-Schrehardt; Michael Kirschfink; Peter F Zipfel; Bernd Hoppe
Journal:  Pediatr Nephrol       Date:  2006-09-23       Impact factor: 3.714

4.  Prevention of C5 activation ameliorates spontaneous and experimental glomerulonephritis in factor H-deficient mice.

Authors:  M C Pickering; J Warren; K L Rose; F Carlucci; Y Wang; M J Walport; H T Cook; M Botto
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-12       Impact factor: 11.205

Review 5.  Kidney Disease Caused by Dysregulation of the Complement Alternative Pathway: An Etiologic Approach.

Authors:  An S De Vriese; Sanjeev Sethi; Jens Van Praet; Karl A Nath; Fernando C Fervenza
Journal:  J Am Soc Nephrol       Date:  2015-07-16       Impact factor: 10.121

Review 6.  Partial lipodystrophy, mesangiocapillary glomerulonephritis, and complement dysregulation. An autoimmune phenomenon.

Authors:  Y Levy; J George; E Yona; Y Shoenfeld
Journal:  Immunol Res       Date:  1998-08       Impact factor: 2.829

Review 7.  Renal disease associated with inherited disorders of the complement system.

Authors:  Thomas R Welch; Lisa W Blystone
Journal:  Pediatr Nephrol       Date:  2008-10-29       Impact factor: 3.714

8.  Hereditary partial deficiency of the third component of complement associated with minimal change nephrotic syndrome.

Authors:  J E Springate; R H McLean; J A Winkelstein; L G Feld
Journal:  Pediatr Nephrol       Date:  1987-10       Impact factor: 3.714

Review 9.  Translational mini-review series on complement factor H: renal diseases associated with complement factor H: novel insights from humans and animals.

Authors:  M C Pickering; H T Cook
Journal:  Clin Exp Immunol       Date:  2008-02       Impact factor: 4.330

10.  Factor H facilitates the clearance of GBM bound iC3b by controlling C3 activation in fluid phase.

Authors:  Danielle Paixão-Cavalcante; Steven Hanson; Marina Botto; H Terence Cook; Matthew C Pickering
Journal:  Mol Immunol       Date:  2009-05-02       Impact factor: 4.407

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.